Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised medicine.
Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions (56 drug combinations x 20 replicates) on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments. This research, incorporating fundamental science alongside clinical expertise at Aachen University Hospital, was led by EMBL group leader Christoph Merten and Julio Saez-Rodriguez, former group leader at EMBL-EBI and now Professor at Heidelberg University.
Small biopsies, many drugs
Directly testing multiple cancer drugs on biopsies – parts of the tumour which have been taken from a patient – is a powerful way to discover which drugs work best, and for whom. This is because depending on the specific tumour characteristics, cancer therapies can be more effective in some people than others. However, large-scale patient specific drug screenings have so far been limited by the small biopsy size that can typically be obtained from patients. That is why in the current paper, the team developed a miniaturised device which can test more drugs on a limited number of cells.
The research team initially tested 56 drug combinations on two different human cancer cell types grown in the lab. Drug combinations which killed both types of cancer cells were thought to be potentially toxic and thus unsafe for further testing. However, some drug combinations which targeted and killed only one type of cancer cell were found to be more effective than standard clinical therapies which only use one drug. These results were highly reproducible and could be validated in mouse models of human cancer.
Subsequently, cells from four cancer patient biopsies were applied to the microfluidic device and different drug combinations were tested. “We found that each individual cancer responded best to a different combination of drugs, highlighting the urgent need for patient-specific therapies,” says Federica Eduati, joint first author on the paper alongside Ramesh Utharala who designed and developed the microfluidic device.
“Before we transfer this technology into the clinics, we need to repeat these experiments in larger-scale mouse studies to understand which types of cancer this technology works best in,” says Christoph Merten. “Still, this is an exciting ‘proof of principle’ collaboration between scientists and clinicians, and we have shown that these tests can be run quickly and for less than $150 USD per patient.”
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Personalized Medicine Market to Register Significant Gains Over 2019 to 2026on March 19, 2020 at 11:14 pm
Personalized Medicine Market (by product:Therapeutics) (by product:Diagnostics) (by product:Personalized Nutrition & Wellness) (by product:Personalized Medical Care) – Global Industry Analysis, Market ...
- Global Population Health Management Markets, 2020-2025 - Emerging Opportunities in Personalized and Value-Based Medicineon March 19, 2020 at 5:39 pm
Dublin, March 19, 2020 -- The "Population Health Management Market by Component (Software, Services), Mode of Delivery (On-premise Mode of Delivery, Cloud-based Mode of.
- Personalized Medicine Market Competitive Outlookon March 19, 2020 at 5:23 am
The Personalized Medicine Market Research Report is a useful research manual that provides basic data on each part of the business that is required for the development of teleological choice and ...
- New Personalized Medicine Findings from Washington University Describedon March 17, 2020 at 4:01 pm
2020 MAR 17-- By a News Reporter-Staff News Editor at Insurance Daily News-- Investigators discuss new findings in Drugs and Therapies- Personalized Medicine. According to news originating from St.
- Key Advances in Sarcoma Lead to More Personalized Medicine Effortson March 17, 2020 at 6:39 am
Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more ...
- Personalized Medicine Market 2020 Global Market Size, Analysis, Share, Research, Business Growth and Forecast to 2026 Research Reports Worldon March 16, 2020 at 1:01 am
Mar 16, 2020 (The Expresswire) -- Global "Personalized Medicine Market" 2020 Industry Research Report is a professional and in-depth study on the current state of the Global Personalized Medicine ...
- Hua Medicine Announces 2019 Annual Resultson March 15, 2020 at 10:19 pm
Pivotal Phase III Trial Achieved Clinical Efficacy Endpoint at 24 WeeksDorzagliatin-Driven Portfolio Expands SHANGHAI, China, March 16, 2020 ...
- Global Personalized Medicine Study, 2018-2028: Focus on Scientific & Commercial Aspects and Profiles of 338 Companies Involvedon March 12, 2020 at 6:13 pm
The "Personalized Medicine - Scientific & Commercial Aspects" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering. This report describes the latest concepts of ...
- The Future Of Healthcare: Data-Driven Personalized Medicine At Scaleon March 11, 2020 at 5:31 am
Huge challenges remain, but unlocking data will generate insights and knowledge that improve the efficiency and effectiveness of the healthcare system.
via Bing News